Dihydroxy-E,Z,E-PUFA

$4.63 Billion Worldwide Omega 3 Ingredients Industry to 2027 - Featuring Corbion, Croda International, Koninklijke DSM and Omega Protein Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 17, 2023
Cosmetics, Retail, Health, Fitness & Nutrition, Specialty, Vitamins, Supplements, Food, Beverage, Pollution, Omega-3 fatty acid, Drink, Hypertriglyceridemia, EPA, Blood, Ageing, COVID-19, Heart, Government, Skin, Eicosapentaenoic acid, Conditional sentence, Dermatitis, Immune system, DHA, Growth, Dietary supplement, Dihydroxy-E,Z,E-PUFA, Alpha-Linolenic acid, ALA, Nutrient, Infant, Obesity, Tuna

Omega 3 ingredients are naturally occurring polyunsaturated fatty acids (PUFAs) and nutrients that are imperative for optimal human health.

Key Points: 
  • Omega 3 ingredients are naturally occurring polyunsaturated fatty acids (PUFAs) and nutrients that are imperative for optimal human health.
  • They are widely found in fish, flaxseed, and dietary supplements, such as algal, krill, refined tuna, and fish oil.
  • Omega 3 ingredients help structure the cell walls, provide energy, and maintain the optimum functioning of the heart, blood vessels, lungs, immune system, and endocrine systems.
  • Additionally, the increasing consumer preference towards high-quality supplement products due to hectic lifestyles and busy schedules is favoring the market growth.

Global Omega-3 Product Market to Reach $4 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 15, 2022
Fitness & Nutrition, Health, Prostate, Capsule, Life, Soybean, Scaly, Endangered Species Act of 1973, Health, Policy, Endangered species, Government, Degenerative disease, Allergy, Colon, Cardiac arrest, Suggestion, Rectum, Cancer, Immunity, Fish, Skin, Tablet, Common Fisheries Policy, Fishery, Dihydroxy-E,Z,E-PUFA, Common, Lung, Stomach, Growth, Rash, Infection, Risk, Dietary supplement, Death, WHO, COVID-19, Magnuson–Stevens Fishery Conservation and Management Act, World Health Organization, Patient, Application

The "Global Omega-3 Product Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Source, Application, and Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Omega-3 Product Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Source, Application, and Region" report has been added to ResearchAndMarkets.com's offering.
  • Moreover, allergies related to fish oil and complex extraction procedure is also restraining the Omega-3 Product Market growth.
  • Omega-3 has been proven beneficial in boosting immunity to help fight COVID-19 and has increased the growth of the omega-3 product market.
  • In addition, the report also covers market size and forecasts for the four regions in the Omega-3 Product Market.

Noster Microbiome Research: Analyzing Bacterial Digest

Retrieved on: 
Friday, December 2, 2022
Bacteria, Human, Feces, LC-MS/MS, Fat, Health, Virus, Sugar, Animal, Tissue, Enzyme, Protein, Dihydroxy-E,Z,E-PUFA, LC, Keio University, Carbohydrate, Mouse, Dietary supplement, Perfume, Liquid

Carbohydrates, such as sugars, fibers and starches, for example, require bacterial intervention to be properly broken down.

Key Points: 
  • Carbohydrates, such as sugars, fibers and starches, for example, require bacterial intervention to be properly broken down.
  • The scientists tested their method by analyzing mouse feces; they successfully detected several fatty acid metabolites produced by the gut microbiota.
  • It combines liquid chromatography, a technique used for physically separating substances, and mass spectroscopy, used for analyzing masses of substances.
  • LC-MS/MS can be used for analyzing a wide range of chemical compounds, including metabolites.

Noster Microbiome Research: Analyzing Bacterial Digest

Retrieved on: 
Friday, December 2, 2022
Bacteria, Human, Feces, LC-MS/MS, Fat, Health, Virus, Sugar, Animal, Tissue, Enzyme, Protein, Dihydroxy-E,Z,E-PUFA, LC, Keio University, Carbohydrate, Mouse, Dietary supplement, Perfume, Liquid

Carbohydrates, such as sugars, fibers and starches, for example, require bacterial intervention to be properly broken down.

Key Points: 
  • Carbohydrates, such as sugars, fibers and starches, for example, require bacterial intervention to be properly broken down.
  • The scientists tested their method by analyzing mouse feces; they successfully detected several fatty acid metabolites produced by the gut microbiota.
  • It combines liquid chromatography, a technique used for physically separating substances, and mass spectroscopy, used for analyzing masses of substances.
  • LC-MS/MS can be used for analyzing a wide range of chemical compounds, including metabolites.

Asia-Pacific Polyunsaturated Fatty Acids (PUFAs) Market Report 2022: Growing Awareness Regarding Health Benefits of Omega-3 & Increasing Cases of Chronic Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Health, Pharmaceutical, Depression, Fish, Face, Population, Growth, Myocardial infarction, Brain, Microalgae, Dihydroxy-E,Z,E-PUFA, Plant, Research, Cancer, PUFA, Food, Vegetable, Diatom, Conditional sentence, Ageing, Urbanization, Awareness, Capsule, CAGR, Thrombosis, Atherosclerosis, Diabetes, Nutrient, Hypertension, Powder, Chronic condition, Plant sources of anti-cancer agents, Human, Retina, Animal, Arthritis, Dietary supplement, Health, Agriculture, Application

The growth in the APAC PUFAs market is expected to be driven by increasing awareness regarding the health benefits of PUFAs, support from government organizations and institutions, and increasing chronic diseases.

Key Points: 
  • The growth in the APAC PUFAs market is expected to be driven by increasing awareness regarding the health benefits of PUFAs, support from government organizations and institutions, and increasing chronic diseases.
  • Furthermore, the PUFA market has been witnessing a shifting trend from animal-based to plant-based PUFA products.
  • animal-based has the largest share in the PUFAs market, due to the increasing awareness regarding holistic lifestyle choices and environmental concerns plant-based is the fastest growing market in the Asia-Pacific region.
  • As the consumer awareness towards global environmental concerns is driving the demand for sustainable ingredients and products across the globe is increasing.

Global Omega-3 Supplements Market Forecast to 2028: Analysis by Form (Capsules, Soft Gels, and Others), & Source (Fish Oil, Krill Oil, Algae Oil, and Others) - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 24, 2022
Alternative Medicine, Health, Fitness & Nutrition, Online, Reckitt, CAGR, Blood pressure, Absorption, Triglyceride, Degenerative disease, Growth, Macular degeneration, Tablet, Supermarket, Health, Plant, Capsule, Prevalence, Dihydroxy-E,Z,E-PUFA, DHA, Pharmavite, Severe cognitive impairment, Person, Eicosapentaenoic acid, EPA, Asthma, Dietary supplement, 2017 Nordic Naturals Challenger

Omega-3 supplements contain EPA and DHA derived from various sources such as fish oil, krill oil, algal oil, and others.

Key Points: 
  • Omega-3 supplements contain EPA and DHA derived from various sources such as fish oil, krill oil, algal oil, and others.
  • The rising prevalence of cardiovascular diseases and increasing healthcare expenses are boosting the growth of the global omega-3 supplements market.
  • By form, the omega-3 supplements market is segmented into capsules, soft gels, and others.
  • By source, the omega-3 supplements market is segmented into fish oil, krill oil, algae oil, and others.

Nannochloropsis-derived Lipids Markets: Human Nutrition, Animal Nutrition, and Other Applications - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 11, 2022
Food, Beverage, Retail, CAGR, F&B, Dietary supplement, DHA, Infant, Population, Drink, Ageing, Growth, Health, Obesity, Industry, Animal nutrition, Degenerative disease, Biomass, Diabetes, Human nutrition, Dihydroxy-E,Z,E-PUFA, Prevalence, Brain, Organic acid, Awareness, Soap, Nannochloropsis, Medication

The "Nannochloropsis-derived Lipids Market by Application (Human Nutrition (Health Supplements & Nutraceuticals, Pharmaceuticals, Other Human Nutritional Applications), Animal Nutrition, and Other Applications) - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nannochloropsis-derived Lipids Market by Application (Human Nutrition (Health Supplements & Nutraceuticals, Pharmaceuticals, Other Human Nutritional Applications), Animal Nutrition, and Other Applications) - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Nannochloropsis-derived lipids (fatty acids) market is expected to record a CAGR of 8.5% from 2021 to 2028 to reach $4.2 million by 2028.
  • Based on application, the Nannochloropsis derived lipids (fatty acids) market is mainly segmented into human nutrition, animal nutrition, and other applications.
  • Who are the local emerging players in the global Nannochloropsis-derived lipids (fatty acids) market, and how do they compete with the global players?

Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit

Retrieved on: 
Tuesday, October 19, 2021
ALS, IND, Visual impairment, Tissue, Death, PUFA, Cell damage, Investigational New Drug, Western world, FA, Reading, Oxidative stress, GLOBE, Patient, University, INAD, Animal, RT001, LA, Retinal pigment epithelium, Demonstration, GA, AMD, Infantile neuroaxonal dystrophy, Collection, Amyotrophic lateral sclerosis, Time, DHA, University of Pennsylvania, Vicious Circle, RATS, Disease, Drusen, LPO, Time-invariant system, Retina, Dihydroxy-E,Z,E-PUFA, Geographic atrophy, Inflammation, Central retinal artery occlusion, Degenerative disease, Dry, Injection, Â, Severe cognitive impairment, RPE, Lipid peroxidation, LOS, Program, Research, Stress (linguistics), PSP, Therapy, Vaccine, Pharmaceutical industry, Dietary supplement

LOS ALTOS, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that positive results from preclinical studies of RT011, the second compound to emerge from the company’s novel technology platform, are being reported in multiple oral presentations at the 2nd Annual Dry AMD Therapeutic Development Summit. Findings to be presented demonstrate that RT011, which is being developed as an oral therapy for the treatment of dry age-related macular degeneration (AMD), provided dose-dependent protection in animal models of oxidative damage implicated in dry AMD. Importantly, study results showed that animals treated with RT011 experienced preservation of retinal cells, photoreceptors, and visual function relative to control animals. The conference, which is being conducted in a virtual format, is being held October 19-21, 2021.

Key Points: 
  • Findings to be presented demonstrate that RT011, which is being developed as an oral therapy for the treatment of dry age-related macular degeneration (AMD), provided dose-dependent protection in animal models of oxidative damage implicated in dry AMD.
  • Importantly, study results showed that animals treated with RT011 experienced preservation of retinal cells, photoreceptors, and visual function relative to control animals.
  • The company expects to file an Investigational New Drug (IND) application for RT011 in the first half of 2022 and initiate first-in-human clinical studies in dry AMD soon thereafter.
  • Study results demonstrated that animals treated with RT011 experienced decreasing levels of retinal damage with increasing tissue concentrations of RT011.

Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)

Retrieved on: 
Wednesday, October 6, 2021
Infantile neuroaxonal dystrophy, Food, PLA2G6, Infant, Degenerative disease, Failure, FA, University of California, Patient, NDA, Lipid peroxidation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, RT001, Hypotonia, Amyotrophic lateral sclerosis, FDA, Disorder, Death, Spasticity, AMD, PSP, Dihydroxy-E,Z,E-PUFA, INAD, University, Food and Drug Administration, LPO, Neurology, Comparative effectiveness research, LA, Disease, Autonomic nervous system, New Drug Application, Pneumonia, HIV disease progression rates, Mitochondrial membrane transport protein, Technology, DHA, ALS, Research, Oxidative stress, Tissue, Brain, Genetics, Radical (chemistry), LOS, Survival, SAP, Membrane, Neurodegeneration, Totality, Seizure, GLOBE, Metabolism, Pharmaceutical industry

LOS ALTOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today reported data from its Phase 2/3 clinical trial of RT001 in patients with infantile neuroaxonal dystrophy (INAD) and its concurrent natural history study of disease onset and progression in INAD patients. Results demonstrated statistically significant improvements in overall survival and progression free survival for patients treated with RT001 as compared to control. These survival endpoints included a combination of efficacy and safety measures. Additionally, clinical improvements were observed in patients receiving RT001 as measured by the Modified Ashworth Spasticity Scale, the study’s primary efficacy endpoint, and other measurements of efficacy as compared to patients in the natural history study. These single efficacy outcomes did not reach statistical significance likely due to the small study size.

Key Points: 
  • Results demonstrated statistically significant improvements in overall survival and progression free survival for patients treated with RT001 as compared to control.
  • The treatment study of RT001 included 19 INAD patients and the concurrent natural history study included 36 INAD patients as the control arm.
  • Patients in the treatment study received RT001 for a minimum period of one year with a 30-day treatment free follow up period.
  • Infantile Neuroaxonal Dystrophy is an ultra-rare, infantile genetic neurological disorder and part of a spectrum of diseases called PLA2G6-associated neurodegeneration.

Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)

Retrieved on: 
Wednesday, August 11, 2021
ALS, Hospital, Radical (chemistry), Amyotrophic lateral sclerosis, Dihydroxy-E,Z,E-PUFA, Speech, Health, Medulla oblongata, Walking, Safety, FA, Caregiver, Patient, Retrotope, Physician, Neurodegeneration, PSP, Lipid peroxidation, Technology, Hannover Medical School, Membrane, Massachusetts General Hospital, Death, Cognition, INAD, Tissue, HIV disease progression rates, LOS, Clinical trial, Brain, Behavior, Government budget balance, RT001, Massachusetts, LA, LPO, Research, Oxidative stress, Cell, Degenerative disease, AMD, Department of Neurology, Xuanwu hospital, History, FDA, Disease, GLOBE, Infantile neuroaxonal dystrophy, Mitochondrial membrane transport protein, Neurology, DHA, Pharmaceutical industry

PSP is a progressive, neurodegenerative disorder that dramatically impacts the health and lives of not only patients, but also their families and other caregivers.

Key Points: 
  • PSP is a progressive, neurodegenerative disorder that dramatically impacts the health and lives of not only patients, but also their families and other caregivers.
  • Study participants have been randomized to receive either RT001 or placebo daily for 48 weeks.
  • The primary endpoint of the trial is change from baseline in the PSP Rating Scale (PSPRS) at 48 weeks.
  • The study also includes several secondary and exploratory endpoints intended to further elucidate the efficacy and safety profile of RT001 as compared to placebo.